Sofinnova Partners SAS - 06 Jan 2022 Form 3 Insider Report for CinCor Pharma, Inc.

Role
10%+ Owner
Signature
Sofinnova Partners SAS, By Monique Saulnier, Managing Partner
Issuer symbol
N/A
Transactions as of
06 Jan 2022
Net transactions value
$0
Form type
3
Filing time
06 Jan 2022, 19:56:08 UTC
Next filing
13 Jan 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding CINC Series A Preferred Stock 06 Jan 2022 Common Stock 2,941,176 By Sofinnova Capital IX F1, F2
holding CINC Series B Preferred Stock 06 Jan 2022 Common Stock 926,470 By Sofinnova Capital IX F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share of Series A Preferred Stock and Series B Preferred Stock will automatically convert into shares of Common Stock on a 3.4:1 basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date.
F2 The shares are directly held by Sofinnova Capital IX ("SC IX"). Sofinnova Partners SAS ("Sofinnova Partners") is the management company of SC IX and may be deemed to share voting and investment power over the shares held by SC IX. Sofinnova Partners disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein.